-
-
Overview
-
Antigen Distribution: FasL is expressed on activated T cells, NK cells, the eye, and testis
Specificity: Clone MFL3 recognizes an epitope on mouse FasL
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Armenian Hamster IgG Isotype Control for In Vivo - Ultra Low Endotoxin [PIP] (ICH2251UL)
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method
Aggregation: Aggregation level ≤ 1%Please contact us at for specific academic pricing.
Background
FasL antibody, clone AFS98, recognizes Fas ligand (FasL), also known as CD178, Apo-1 ligand, and CD95 ligand. FasL is a 40 kDa type II integral membrane protein that belongs to the tumor necrosis factor (TNF) superfamily. FasL is expressed by activated T cells and natural killer (NK cells). Binding of FasL to its receptor Fas (CD95, APO-1) induces apoptotic cell death in Fas-expressing target cells, contributing to anti-viral immunity. FasL also contributes to peripheral tolerance and the downregulation of immune responses through activation-induced autocrine and paracrine T cell death. FasL is also found in the anterior chamber of the eye and on Sertoli cells in the testis, and is implicated in immune-privilege at these sites. FasL also contributes to CD8 proliferation and neutrophil recruitment. Soluble FasL (26 kDa) can be released following cleavage by metalloproteinases and block FasL-mediated signaling. Fas/FasL-signaling is involved in the development of many human diseases, including autoimmunity and cancer. Many human tumors over-express FasL, resulting in tumor infiltrating lymphocyte (TIL) apoptosis and immune evasion, which is associated with poor prognosis.
-
- Properties
- Applications
-
Overview